Lonza Group AG

Chart & Performance

D1W1MN

P/E

5.61

P/S

0.55

EPS

9.50

Div Yield, %

6.36%

Shrs. gr., 5y

-0.28%

Rev. gr., 5y

3.92%

Revenues

6.72b

+7.94%

Net income

654m

-46.17%

CFO

1.39b

+33.59%

Dividend

May 15, 20240.442 USD/sh

Earnings

Jan 30, 2025

Profile

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

URL

https://www.lonza.com/

IPO date

Apr 03, 2002

Employees

17,896

Domiciled in

Incorporated in

Valuation

Order:

Title CHF in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CHF in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	6,717,000 7.94%	6,223,000 15.05%	5,409,000 19.99%
Cost of revenue	5,711,000	4,983,000	4,425,000
Unusual Expense (Income)
NOPBT	1,006,000	1,240,000	984,000
NOPBT Margin	14.98%	19.93%	18.19%
Operating Taxes	135,000	230,000	83,000
Tax Rate	13.42%	18.55%	8.43%
NOPAT	871,000	1,010,000	901,000
Net income	654,000 -46.17%	1,215,000 -58.73%	2,944,000 238.78%
Dividends	(260,000)	(223,000)	(225,000)
Dividend yield	1.00%	0.66%	0.40%
Proceeds from repurchase of equity	(1,011,000)	(51,000)	(204,000)
BB yield	3.88%	0.15%	0.36%
Debt
Debt current	227,000	732,000	219,000
Long-term debt	3,236,000	1,855,000	2,530,000
Deferred revenue	658,000	739,000	675,000
Other long-term liabilities	519,000	762,000	817,000
Net debt	1,490,000	65,000	(716,000)
Cash flow
Cash from operating activities	1,388,000	1,039,000	1,220,000
CAPEX	(1,682,000)	(1,872,000)	(1,346,000)
Cash from investing activities	(1,096,000)	(991,000)	1,018,000
Cash from financing activities	(152,000)	(286,000)	(1,283,000)
FCF	696,000	(958,000)	1,216,000
Balance
Cash	1,668,000	2,224,000	3,184,000
Long term investments	305,000	298,000	281,000
Excess cash	1,637,150	2,210,850	3,194,550
Stockholders' equity	8,118,000	8,197,000	7,307,000
Invested Capital	12,183,850	12,138,150	10,444,450
ROIC	7.16%	8.94%	8.45%
ROCE	7.03%	8.21%	6.83%
EV
Common stock shares outstanding	73,684	74,357	74,490
Price	353.70 -21.94%	453.10 -40.51%	761.60 33.90%
Market cap	26,061,969 -22.64%	33,691,309 -40.61%	56,731,663 33.50%
EV	27,611,969	33,824,309	56,088,663
EBITDA	1,627,000	1,836,000	1,506,000
EV/EBITDA	16.97	18.42	37.24
Interest	93,000	73,000	72,000
Interest/NOPBT	9.24%	5.89%	7.32%